Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulopenem Etzadroxil + Probenecid in Adolescent Patients With Bacterial Infection
NCT07092813Phase 1Recruiting
- Sponsor
- Iterum Therapeutics plc
- Start
- Apr 2026
- Primary completion
- Oct 2026
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alipogene tiparvovec in bacterial infection, sponsored by Iterum Therapeutics plc. Primary endpoints: Sulopenem plasma concentration after dose at 6 hours, Probenecid plasma concentration after dose at 6 hours and 2 more. Started Apr 2026; status: recruiting.
02
Drugs
alipogene tiparvovec
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT07092813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07092813.